Pfizer Ltd, a domestic-focused branded pharmaceuticals company with 96.18% of revenue from India, reports Q2 FY 2026-2027 results into a market where IPM growth accelerated through the quarter — from 12.1% in July to 17.1% in September 2026. The print will speak to whether company growth re-accelerates toward the IPM pace after Q1's 8.31% YoY, and how the Minipress XL exit and the USD 13.9 Million (~Rs. 131.38 Crore) compensation from Pfizer Inc. USA are accounted for.
| Results date | November 03, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 653.17 Cr |
| Previous quarter PAT | Rs. 204.47 Cr |
| Market cap | Rs. 17,244.1 Cr |
| CMP | Rs. 3,759.8 |
The Board of Directors will meet on Tuesday, November 3, 2026, to approve the unaudited financial results for the quarter and half year ended September 30, 2026 (Q2/H1 FY27) under Regulation 29 of SEBI LODR. Per the company's financial calendar, Q2 FY27 results are due on or before November 14, 2026.
The quarter's central question is whether Pfizer Ltd's revenue re-accelerates from Q1 FY27's 8.31% YoY growth toward the IPM's pace, which strengthened every month of the quarter — 12.1% in July, ~13% in August and 17.1% in September 2026, with chronic therapies leading (chronic +16.8% MAT vs acute +10.9% in September). Two company-specific drags temper that read: Minipress XL, a brand with Rs. 228.6 Cr of MAT revenue to July 2026, left the portfolio on September 7, 2026, and market growth was pricing-led with unit growth of just 1.1-1.6% in July-August before September's 3.5-5.4% pickup. On margins, the driver set points to broadly flat against FY26's 35.9% EBITDA margin (Operating Profit Margin 33.59%), with the Minipress exit and the rupee's ~1% net slide over the window (95.25 to 96.1450 per USD) as mild pressures on Belgian-sourced stock-in-trade, offset partly by 5-10% API price deflation into mid-June 2026. There is no outstanding management guidance to test — the only dated commitments are the Rs. 75/share FY26 dividend paid on or after August 4, 2026, and the results calendar. The single biggest quarter-specific swing to listen for is how the USD 13.9 Million (~Rs. 131.38 Crore) Minipress XL compensation from Pfizer Inc. USA is recognised, given Q1 FY27 exceptional items were nil versus FY26's Rs. (49.16) Cr outflow.
Minipress XL compensation accounting: The largest quarter-specific swing factor for reported numbers.
Cipla arrangement execution: Early read on the exclusive supply and marketing arrangement for four brands.
Growth and margin trajectory: Whether growth re-accelerates and where margins land.
New launch momentum: Portfolio build from recent launches.
Cash deployment and tax-contingency updates: Balance-sheet and litigation items on the call agenda.
Pfizer Ltd discontinued Minipress XL effective September 7, 2026, after Pfizer Inc. USA stopped manufacturing it, and will receive a lump-sum payment of USD 13.9 Million (~Rs. 131.38 Crore). The timing and P&L line of recognition were not disclosed, so whether it lands in other income, as an exceptional item, or is deferred is the biggest quarter-specific swing factor.
Pfizer Ltd entered an exclusive supply and marketing agreement with Cipla Limited for the marketing and distribution of four brands: Corex Dx, Corex LS, Dolonex and Neksium. The company made a Rs. 41.73 Crore charge in FY26 covering personnel separation costs for field force and marketing teams as a result of the arrangement.
Revenue from operations was Rs. 653.17 Cr in Q1 FY27, up 8.31% YoY from Rs. 603.05 Cr in Q1 FY26 and up 3.80% QoQ from Rs. 629.23 Cr in Q4 FY26. Net profit was Rs. 204.47 Cr, up 6.63% YoY.
IPM value growth accelerated through the quarter — 12.1% YoY in July 2026, ~13% in August and 17.1% in September per Equirus Securities, the strongest monthly print in three years. Growth was chronic-led, which maps onto Pfizer Ltd's branded portfolio given its FY26 chronic skew (chronic +13.6% vs acute +7.5%).
An order dated September 25, 2026 levied a penalty of Rs. 1,26,34,050 under Section 271G of the Income-tax Act, 1961 for alleged non-furnishing of information during the Transfer Pricing audit for AY 2023-24. The company considers the order not maintainable, is preferring an appeal, and expects no material impact on its financial position or operations.